Profound Medical Reports Record-Breaking Third Quarter Revenue

TORONTO, Oct. 07, 2026 /CourierPR/ -- Profound Medical Corp., a commercial-stage medical device company, reported preliminary unaudited revenues for the third quarter ended September 30, 2026, marking a significant milestone for the firm. The company expects to surpass its previous financial records, with revenues anticipated to fall within the range of $9.8 million to $10.0 million, a substantial increase from the $5.3 million reported in the same period of the previous year.

According to the press release, the growth in revenue is expected to be approximately 85% to 89% year-over-year, reflecting a significant boost in commercial activity. This growth is even more impressive when compared to the second quarter of 2026, where revenues were only $2.5 million, indicating a sequential quarter-over-quarter increase of 292% to 300%.

The anticipated revenue is also expected to be approximately 45% to 47% above the Bloomberg mean analyst consensus of $6.78 million, as of October 7, 2026, at 9:02 a.m. ET. Profound Medical Corp. attributes this success to the continued progress in its commercial operations and scale, with the gross margin for the third quarter of 2026 expected to exceed 70%.

Profound Medical Corp. intends to report full third quarter 2026 financial results after the market close on Thursday, November 5, 2026. The company will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. The call will be live and archived on the Company's website in the Investors section, with registration available at the provided link: register-conf.media-server.com/register/BI38c9375e5dd147bc971da6a4bb029d8c.

The release also highlights the company's technologies, including its flagship platform, TULSA-PRO®, which enables MRI-guided, incision-free prostate ablation. Physicians use the TULSA Procedure™ to see, ablate, and confirm therapy in real time, supporting personalized treatment strategies across the continuum of prostate care, from whole-gland to subtotal, hemi, multifocal, and focal treatment. This approach enables individualized care using prostate tissue ablation, while minimizing the potential of the side effects that are typically associated with surgery or radiation, such as urinary incontinence and/or erectile dysfunction.

Profound also commercializes Sonalleve®, an MRI-guided therapy that provides a non-surgical treatment option for pain palliation of bone metastases, desmoid tumors, and osteoid osteoma, as well as for common gynecologic conditions including uterine fibroids and adenomyosis. Sonalleve delivers targeted therapy with no incisions, no blood loss during the procedure, no overnight hospital stay, and faster recovery, and, in gynecologic applications, enables uterine-sparing treatment that may help preserve fertility. Profound is also exploring additional clinical applications for Sonalleve, including non-invasive ablation of abdominal cancers and hyperthermia-based cancer therapies.

Through real-time MRI guidance and data-driven innovation, Profound is advancing the future of MRI-guided therapy, expanding access to precise, personalized, and incision-free treatment options worldwide.